A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

This Phase 2 study evaluates the safety, tolerability, and effectiveness of HRS-1893 — an experimental drug — in adults with non-obstructive hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood efficiently without causing blockage. Researchers are testing different dosing regimens to find the right balance of benefit and safety. Eligible participants are adults aged 18–85 with a BMI under 35 who have non-obstructive HCM and do not have a history of syncope, sustained heart rhythm problems, or other serious conditions. Participation involves taking the study medication and attending regular clinic visits for monitoring of heart function, drug levels in the blood, and safety assessments. This summary was prepared to help patients understand the study in plain language.